Trial: AZD0901 Compared With Investigator's Ch…

Trial Details

Sponsor: AstraZeneca (industry)

Phase: 3

Start date: March 4, 2024

Planned enrollment: 572

Trial ID: NCT06346392

More trial details at ClinicalTrials.gov

Show Summary from Sponsor

Investigational Drug AI Analysis

Show for: AZD0901 (Sonesitatug vedotin, CMG901)

Overview

AZD0901 (sonesitatug vedotin; formerly CMG901) is an investigational antibody–drug conjugate (ADC) targeting claudin 18.2 (CLDN18.2), being developed primarily for gastric/gastroesophageal junction (G/GEJ) adenocarcinoma and other CLDN18.2-expressing solid tumors. Early-phase clinical data show antitumor activity with a manageable safety profile in previously treated CLDN18.2-positive G/GEJ cancer, and multiple phase 2 and phase 3 trials are ongoing. (pubmed.ncbi.nlm.nih.gov)

Mechanism of action

Target: CLDN18.2, a tight-junction protein aberrantly exposed in several gastrointestinal cancers. (pubmed.ncbi.nlm.nih.gov)
Construct: Humanized anti‑CLDN18.2 IgG1 linked via a protease‑cleavable linker to monomethyl auristatin E (MMAE; “vedotin”). The ADC mediates direct cytotoxicity after internalization and MMAE release, plus immune effector functions (ADCC/CDC) and a bystander effect. (pubmed.ncbi.nlm.nih.gov)

Efficacy

Phase 1 (KYM901, NCT04805307) in advanced G/GEJ cancer (mostly CLDN18.2-positive; Q3W dosing 2.2–3.0 mg/kg):
Confirmed ORR 28% (95% CI 20–38; 32/113) in the full analysis set; ORR 29% (95% CI 21–39; 32/109) in the efficacy set; recommended phase 2 dose (RP2D) 2.2 mg/kg. Median follow-up 9.0 months. (pubmed.ncbi.nlm.nih.gov)
Earlier ASCO abstract reported, among 93 CLDN18.2-positive patients, confirmed ORR 32.6% and median PFS 4.76 months; 9‑month OS rate 56.4%. Data cutoff July 24, 2023. (ascopubs.org)

Ongoing trials (selected): - CLARITY-PanTumor01 (Phase 2, NCT06219941): AZD0901 monotherapy and combinations in advanced CLDN18.2-expressing tumors (G/GEJ, PDAC); primary endpoints include safety and ORR. Recruitment began December 2023. (ascopubs.org) - GEMINI-Gastric (Master Phase 2, NCT05702229): evaluates novel agents including AZD0901 in combination with chemotherapy/immunotherapy in metastatic gastric cancer. (ascopubs.org) - Randomized Phase 3 (NCT06346392): AZD0901 vs ramucirumab/paclitaxel (or investigator’s taxane) in second-line G/GEJ adenocarcinoma; primary completion estimated April 2026. (cdek.pharmacy.purdue.edu)

Safety

Phase 1 dose-escalation/expansion:
Most common treatment-emergent adverse events (any grade): vomiting, decreased appetite, proteinuria, anemia. Grade ≥3 AEs most frequently included decreased neutrophil count (≈21%), anemia (≈14%), and vomiting (≈10%); one treatment-related death reported. Maximum tolerated dose not reached; RP2D 2.2 mg/kg Q3W. (pubmed.ncbi.nlm.nih.gov)
Earlier ASCO readout listed common AEs: anemia, vomiting, hypoalbuminemia; grade ≥3 neutrophil count decreased 18.6% and anemia 13.3%. (ascopubs.org)

Class-related considerations: As an MMAE-bearing ADC, AZD0901’s toxicity profile aligns with other vedotin ADCs (e.g., myelosuppression, GI AEs), consistent with preclinical findings attributing reversible hematopoietic changes to the payload. (pubmed.ncbi.nlm.nih.gov)

Additional notes

Naming and sponsorship: Originally developed as CMG901 by KYM Biosciences (Keymed/Lepu); globally licensed to and now developed by AstraZeneca (AZD0901; USAN nonproprietary name sonesitatug vedotin). (news.cision.com)
Dosing schedule under study: Intravenous administration every 3 weeks (Q3W). RP2D 2.2 mg/kg in Phase 1. (pubmed.ncbi.nlm.nih.gov)

Show for: Apatinib (Rivoceranib)

Overview

Apatinib (international nonproprietary name: rivoceranib) is an oral small‑molecule tyrosine kinase inhibitor that selectively targets VEGFR‑2 to inhibit tumor angiogenesis. It is approved in China (as apatinib, brand Aitan) for advanced gastric cancer and, in combination with the PD‑1 inhibitor camrelizumab, as a first‑line option for unresectable hepatocellular carcinoma (HCC); outside China it remains investigational. (pubmed.ncbi.nlm.nih.gov)

Mechanism of action

Rivoceranib selectively inhibits VEGFR‑2 with nanomolar potency (biochemical IC50 ≈16 nM) and shows higher kinome selectivity versus several approved VEGFR2 inhibitors, consistent with a class toxicity profile driven largely by on‑target anti‑VEGF effects. (link.springer.com)

Efficacy

Gastric/GEJ adenocarcinoma (post‑chemotherapy):
Phase III, randomized, double‑blind, placebo‑controlled trial in China (n=267): apatinib improved overall survival (OS) 6.5 vs 4.7 months (HR 0.71) and progression‑free survival (PFS) 2.6 vs 1.8 months; common grade 3–4 events were hand–foot syndrome, proteinuria, and hypertension. (pubmed.ncbi.nlm.nih.gov)
Global Phase III ANGEL study (n=460): rivoceranib did not improve OS in the ITT population (5.78 vs 5.13 months; HR 0.93; p=0.47) but improved PFS (2.83 vs 1.77 months; HR 0.58), ORR (6.5% vs 1.3%), and DCR (40.3% vs 13.2%); a prespecified ≥4th‑line subgroup showed OS and PFS benefits. (link.springer.com)
Hepatocellular carcinoma:
RESCUE Phase II (nonrandomized; camrelizumab + apatinib): first‑line cohort ORR 34.3% (95% CI 23.3–46.6) and second‑line cohort ORR 22.5%; median PFS 5.7 and 5.5 months, respectively; 12‑month OS rates 74.7% and 68.2%. (pubmed.ncbi.nlm.nih.gov)
Phase Ib/II cohort A (advanced primary liver cancer): ORR 10.7%; median PFS 3.7 months; median OS 13.2 months. (pubmed.ncbi.nlm.nih.gov)
TRIPLET Phase II (camrelizumab + apatinib + HAIC‑FOLFOX in BCLC‑C): confirmed ORR 77.1% and DCR 97.1% in a 35‑patient single‑arm study. (pubmed.ncbi.nlm.nih.gov)
Non–small cell lung cancer:
Randomized multicenter trial (second‑line; apatinib + single‑agent chemotherapy vs chemotherapy; n=37): median PFS 5.47 vs 2.97 months; ORR 27% vs 9%; DCR 95% vs 73%. (pubmed.ncbi.nlm.nih.gov)
Earlier randomized Phase II (third‑line; nonsquamous NSCLC; apatinib vs placebo; n=135): median PFS 4.7 vs 1.9 months; RR 12.2% vs 0%; DCR 68.9% vs 24.4%. (ascopubs.org)
Additional gastric cancer experiences:
Real‑world and exploratory combinations (e.g., with S‑1) show modest activity consistent with prior trials; outcomes depend on setting and regimen. (pubmed.ncbi.nlm.nih.gov)

Safety

Across studies, the safety profile reflects VEGF‑pathway inhibition. Common adverse events include hypertension, proteinuria, and hand–foot skin reaction; hematologic AEs (e.g., anemia, thrombocytopenia) and fatigue are also observed. Grade ≥3 events frequently include hypertension and proteinuria, with event rates varying by regimen and indication (e.g., in ANGEL: grade ≥3 hypertension 17.9%, proteinuria 7.5%; in RESCUE combination: grade ≥3 TRAEs in 77.4% with hypertension most common). Treatment‑related deaths were rare. (link.springer.com)

HealthScout AI Analysis

Goal: Evaluate whether AZD0901 improves progression-free survival and overall survival versus investigator’s choice of therapy as second- or later-line treatment in advanced/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma expressing Claudin 18.2, and concurrently assess the clinical performance of the Ventana CLDN18.2 assay as a companion diagnostic.

Patients: Adults (≥18 years) with histologically confirmed unresectable, locally advanced or metastatic gastric, GEJ, or distal esophageal adenocarcinoma that is Claudin 18.2–positive on archival (≤24 months) or fresh biopsy. Patients must have progressed after at least one prior systemic line containing a fluoropyrimidine and platinum, have measurable or evaluable disease by RECIST 1.1, ECOG 0–1, life expectancy ≥12 weeks, and adequate organ function. Key exclusions include HER2-positive disease, significant or unstable gastric bleeding/ulcer, active or recent CNS disease, clinically significant corneal disease, unresolved ≥Grade 2 toxicities, prior ADC with an MMAE payload or prior CLDN18.2-targeted therapies beyond naked antibodies, and recent thromboembolic events.

Design: Global, multicenter, open-label, sponsor-blinded, randomized Phase III trial with approximately 572 participants assigned to AZD0901 or investigator’s choice of therapy. The study includes biomarker-driven enrollment based on CLDN18.2 expression and incorporates blinded independent central review for efficacy assessments.

Treatments: Experimental: AZD0901 intravenous infusion (two dose levels were planned; enrollment to Arm 2 closed). AZD0901 (sonesitatug vedotin; formerly CMG901) is a Claudin 18.2–targeted antibody–drug conjugate that delivers the microtubule inhibitor MMAE via a cleavable linker; it also mediates Fc-dependent immune effector functions and bystander killing. In Phase 1 gastric/GEJ cohorts, confirmed objective response rate was about 28%–33% with median duration of response around 8 months and manageable but notable Grade ≥3 toxicities including neutropenia, anemia, and vomiting; randomized data are pending. Comparator: Investigator’s choice of regionally accepted regimens, including ramucirumab plus paclitaxel, paclitaxel, docetaxel, irinotecan, TAS-102, or apatinib, each representing standard second- or later-line options depending on regional availability and prior exposure.

Outcomes: Dual primary endpoints are progression-free survival in all randomized participants and overall survival in the subgroup treated in third line or later. Key secondary endpoints include overall survival in all randomized participants, PFS in third line or later, objective response rate and duration of response by BICR per RECIST 1.1, safety and tolerability, pharmacokinetics of AZD0901, total antibody and MMAE, and immunogenicity including ADA prevalence/incidence and titers.

Burden on patient: Moderate. Patients will undergo CLDN18.2 testing, which may require a fresh biopsy if recent archival tissue is not available. Imaging for PFS/ORR by central review will be on a regular schedule similar to standard-of-care follow-up. As an ADC study, there will be intravenous infusions on a repeating cycle, safety labs, ECGs, and focused ophthalmologic monitoring given exclusion of corneal disease. The protocol includes pharmacokinetic and immunogenicity sampling for AZD0901, total antibody, MMAE, and ADA, which adds extra blood draws beyond routine care. Travel burden aligns with typical chemotherapy schedules; overall intensity exceeds that of purely oral regimens but is comparable to other second-line IV therapies with added PK/ADA assessments.

Last updated: Oct 2025

Eligibility

Show Criteria

Inclusion Criteria:

1. Capable of giving signed informed consent prior to any study procedure.

2. Participant must be at least 18 years or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the ICF.

3. Histologically confirmed unresectable, locally advanced or metastatic adenocarcinoma of gastric, GEJ, or distal esophagus (distal third of the esophagus) and the following requirement:

(a) Participants with positive CLDN18.2 expression from archival tumor collected within past 24 months or from a fresh biopsy.

4. Disease progression on or after at least one prior line of treatment (LoT) for advanced or metastatic disease, which included a fluoropyrimidine and a platinum, for advanced or metastatic disease.

5. Must have at least one measurable or evaluable lesion assessed by the Investigator based on RECIST 1.1.

6. ECOG performance status of 0 or 1 with no deterioration over the previous 2 weeks prior to baseline or day of first dosing.

7. Predicted life expectancy of ≥ 12 weeks.

8. Adequate organ and bone marrow function

9. Body weight of ≥ 35 kg.

10. Sex and Contraceptive Requirements

Exclusion Criteria:

1. Participants with known HER2 positive status as defined as IHC 3+ or IHC 2+/ISH + (Cases with HER2: CEP17 ratio ≥ 2 or an average HER2 copy number ≥ 6.0 signals/cell are considered positive by ISH). Participants must undergo local (or have had) HER2 testing by IHC/ISH, and the most recent result of HER2 status will be used to determine the eligibility.

2. Participant has significant or unstable gastric bleeding and/or untreated gastric ulcers.

3. CNS metastases or CNS pathology including: epilepsy, seizures or aphasia within 3 months prior to consent, severe brain injury, dementia, Parkinson's disease, neurodegenerative diseases, cerebellar disease, severe uncontrolled mental illness, psychosis, CNS involvement of autoimmune diseases.

4. Participant has known clinically significant corneal disease (eg, active keratitis or corneal ulcerations).

5. Persistent toxicities (CTCAE Grade ≥ 2) caused by previous anticancer therapy, excluding alopecia. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention may be included (eg, hearing loss).

6. Prior exposure to any ADC with MMAE payload or any CLDN18.2 targeting treatment other than naked monoclonal antibody (eg, CLDN18.2 targeting CAR-T cell therapy, multi-specific antibody including targeting CLDN18.2, etc).

7. History of thromboembolic events:

1. Participants with venous thromboembolism within the past 6 months prior to randomization: participants with venous port or catheter thrombosis or superficial venous thrombus that do not require treatment or are stable on treatment with anticoagulants are excepted

2. History of arterial thromboembolism within the past 12 months prior to randomization

8. As judged by the Investigator, any evidence of diseases which in the Investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol.

Sites (186)

Sort by distance to:

Research Site

Vitória, 29043-272, Brazil

No email / No phone

Status: Recruiting

Research Site

Ribeirão Preto, 14051-140, Brazil

No email / No phone

Status: Recruiting

Research Site

São Paulo, 05652-900, Brazil

No email / No phone

Status: Recruiting

Research Site

Toronto, Ontario, M5G 2M9, Canada

No email / No phone

Status: Recruiting

Research Site

Ottawa, Ontario, K1H 8L6, Canada

No email / No phone

Status: Recruiting

Research Site

North York, Ontario, M2K 1E1, Canada

No email / No phone

Status: Recruiting

Research Site

London, Ontario, N6C 2R5, Canada

No email / No phone

Status: Recruiting

Research Site

Barrie, Ontario, L4M 6M2, Canada

No email / No phone

Status: Recruiting

Research Site

Montreal, Quebec, H3G 1A4, Canada

No email / No phone

Status: Recruiting

Research Site

Shanghai, 200032, China

No email / No phone

Status: Recruiting

Research Site

Shanghai, 200025, China

No email / No phone

Status: Recruiting

Research Site

Qingdao, 266003, China

No email / No phone

Status: Recruiting

Research Site

Nanjing, 210008, China

No email / No phone

Status: Recruiting

Research Site

Lishui, 323000, China

No email / No phone

Status: Recruiting

Research Site

Lanzhou, 730000, China

No email / No phone

Status: Recruiting

Research Site

Jining, 272029, China

No email / No phone

Status: Recruiting

Research Site

Jinan, 250117, China

No email / No phone

Status: Recruiting

Research Site

Hefei, 230601, China

No email / No phone

Status: Recruiting

Research Site

Hefei, 230031, China

No email / No phone

Status: Recruiting

Research Site

Hefei, 230022, China

No email / No phone

Status: Recruiting

Research Site

Harbin, 150049, China

No email / No phone

Status: Recruiting

Research Site

Hangzhou, 310022, China

No email / No phone

Status: Recruiting

Research Site

Hangzhou, 310020, China

No email / No phone

Status: Recruiting

Research Site

Guangzhou, 510060, China

No email / No phone

Status: Recruiting

Research Site

Guangzhou, 510655, China

No email / No phone

Status: Recruiting

Research Site

Guangzhou, 510120, China

No email / No phone

Status: Recruiting

Research Site

Guangzhou, 510700, China

No email / No phone

Status: Recruiting

Research Site

Zhengzhou, 450003, China

No email / No phone

Status: Recruiting

Research Site

Yinchuan, 750004, China

No email / No phone

Status: Recruiting

Research Site

Xi'an, 710061, China

No email / No phone

Status: Recruiting

Research Site

Wuhan, 430030, China

No email / No phone

Status: Recruiting

Research Site

Wuhan, 430000, China

No email / No phone

Status: Recruiting

Research Site

Ürümqi, 830000, China

No email / No phone

Status: Recruiting

Research Site

Tianjin, 300060, China

No email / No phone

Status: Recruiting

Research Site

Suzhou, 215004, China

No email / No phone

Status: Recruiting

Research Site

Shijiazhuang, 050011, China

No email / No phone

Status: Recruiting

Research Site

Shenyang, 110042, China

No email / No phone

Status: Recruiting

Research Site

Shanghai, 200040, China

No email / No phone

Status: Recruiting

Research Site

Beijing, 100210, China

No email / No phone

Status: Recruiting

Research Site

Changchun, 130021, China

No email / No phone

Status: Recruiting

Research Site

Chengdu, 610000, China

No email / No phone

Status: Recruiting

Research Site

Chengdu, 610042, China

No email / No phone

Status: Recruiting

Research Site

Fuzhou, 350001, China

No email / No phone

Status: Recruiting

Research Site

Fuzhou, 350014, China

No email / No phone

Status: Recruiting

Research Site

Besançon, 25030, France

No email / No phone

Status: Recruiting

Research Site

Brest, 29200, France

No email / No phone

Status: Recruiting

Research Site

Lille, 59037, France

No email / No phone

Status: Recruiting

Research Site

Lyon, 69008, France

No email / No phone

Status: Recruiting

Research Site

Nantes, 44000, France

No email / No phone

Status: Recruiting

Research Site

Paris, 75571, France

No email / No phone

Status: Recruiting

Research Site

Poitiers, 86021, France

No email / No phone

Status: Recruiting

Research Site

Moers, 47441, Germany

No email / No phone

Status: Recruiting

Research Site

Berlin, 10249, Germany

No email / No phone

Status: Recruiting

Research Site

Berlin, 13353, Germany

No email / No phone

Status: Recruiting

Research Site

Frankfurt, 60488, Germany

No email / No phone

Status: Recruiting

Research Site

Göttingen, 37075, Germany

No email / No phone

Status: Recruiting

Research Site

Hamburg, 20246, Germany

No email / No phone

Status: Recruiting

Research Site

Heidelberg, 69120, Germany

No email / No phone

Status: Recruiting

Research Site

Heilbronn, 74078, Germany

No email / No phone

Status: Recruiting

Research Site

Leipzig, 04103, Germany

No email / No phone

Status: Recruiting

Research Site

Marburg, 35043, Germany

No email / No phone

Status: Recruiting

Research Site

München, 81377, Germany

No email / No phone

Status: Recruiting

Research Site

Hong Kong, 150001, Hong Kong

No email / No phone

Status: Recruiting

Research Site

Hong Kong, Hong Kong

No email / No phone

Status: Recruiting

Research Site

Mumbai, 400012, India

No email / No phone

Status: Recruiting

Research Site

Hyderabad, 500032, India

No email / No phone

Status: Recruiting

Research Site

Ahmedabad, 380015, India

No email / No phone

Status: Recruiting

Research Site

New Delhi, 110085, India

No email / No phone

Status: Recruiting

Research Site

Milan, 20133, Italy

No email / No phone

Status: Recruiting

Research Site

Florence, 50134, Italy

No email / No phone

Status: Recruiting

Research Site

Vicenza, 36100, Italy

No email / No phone

Status: Recruiting

Research Site

Pisa, 56100, Italy

No email / No phone

Status: Recruiting

Research Site

Padua, 35128, Italy

No email / No phone

Status: Recruiting

Research Site

Napoli, 80131, Italy

No email / No phone

Status: Recruiting

Research Site

Milan, 20162, Italy

No email / No phone

Status: Recruiting

Research Site

Kashiwa, 227-8577, Japan

No email / No phone

Status: Recruiting

Research Site

Fukuoka, 812-8582, Japan

No email / No phone

Status: Recruiting

Research Site

Kōtoku, 135-8550, Japan

No email / No phone

Status: Recruiting

Research Site

Nagoya, 464-8681, Japan

No email / No phone

Status: Recruiting

Research Site

Ogaki-shi, 503-8502, Japan

No email / No phone

Status: Recruiting

Research Site

Osaka, 541-8567, Japan

No email / No phone

Status: Recruiting

Research Site

Sunto-gun, 411-8777, Japan

No email / No phone

Status: Recruiting

Research Site

Tokyo, 104-0045, Japan

No email / No phone

Status: Recruiting

Research Site

Toyoake-shi, 470-1192, Japan

No email / No phone

Status: Recruiting

Research Site

Yokohama, 241-8515, Japan

No email / No phone

Status: Recruiting

Research Site

Bielsko-Biala, 43-300, Poland

No email / No phone

Status: Recruiting

Research Site

Katowice, 40-514, Poland

No email / No phone

Status: Recruiting

Research Site

Słupsk, 76-200, Poland

No email / No phone

Status: Recruiting

Research Site

Krakow, 31-501, Poland

No email / No phone

Status: Recruiting

Research Site

Lublin, 20-080, Poland

No email / No phone

Status: Recruiting

Research Site

Gdansk, 80-219, Poland

No email / No phone

Status: Recruiting

Research Site

Warsaw, 04-141, Poland

No email / No phone

Status: Recruiting

Research Site

Warsaw, 02-034, Poland

No email / No phone

Status: Recruiting

Research Site

Seoul, 06591, South Korea

No email / No phone

Status: Recruiting

Research Site

Seoul, 06351, South Korea

No email / No phone

Status: Recruiting

Research Site

Seoul, 03722, South Korea

No email / No phone

Status: Recruiting

Research Site

Seoul, 03080, South Korea

No email / No phone

Status: Recruiting

Research Site

Gyeonggi-do, 13620, South Korea

No email / No phone

Status: Recruiting

Research Site

Madrid, 28034, Spain

No email / No phone

Status: Recruiting

Research Site

Barcelona, 08036, Spain

No email / No phone

Status: Recruiting

Research Site

Ourense, 32005, Spain

No email / No phone

Status: Recruiting

Research Site

Santander, 39008, Spain

No email / No phone

Status: Recruiting

Research Site

Seville, 41013, Spain

No email / No phone

Status: Recruiting

Research Site

Madrid, 28041, Spain

No email / No phone

Status: Recruiting

Research Site

Barcelona, 8035, Spain

No email / No phone

Status: Recruiting

Research Site

Lausanne, 1011, Switzerland

No email / No phone

Status: Recruiting

Research Site

Zurich, 8032, Switzerland

No email / No phone

Status: Recruiting

Research Site

Bern, 3010, Switzerland

No email / No phone

Status: Recruiting

Research Site

Geneva, 1205, Switzerland

No email / No phone

Status: Recruiting

Research Site

Kaohsiung City, 00807, Taiwan

No email / No phone

Status: Recruiting

Research Site

Kaohsiung City, 83301, Taiwan

No email / No phone

Status: Recruiting

Research Site

Taichung, 40447, Taiwan

No email / No phone

Status: Recruiting

Research Site

Tainan City, Taiwan

No email / No phone

Status: Recruiting

Research Site

Taipei, 10002, Taiwan

No email / No phone

Status: Recruiting

Research Site

Taipei, 112, Taiwan

No email / No phone

Status: Recruiting

Research Site

Taoyuan District, 333, Taiwan

No email / No phone

Status: Recruiting

Research Site

Khon Kaen, 40002, Thailand

No email / No phone

Status: Recruiting

Research Site

Hat Yai, 90110, Thailand

No email / No phone

Status: Recruiting

Research Site

Dusit, 10300, Thailand

No email / No phone

Status: Recruiting

Research Site

Bangkok, 10700, Thailand

No email / No phone

Status: Recruiting

Research Site

Istanbul, 34098, Turkey (Türkiye)

No email / No phone

Status: Recruiting

Research Site

Erzurum, 25240, Turkey (Türkiye)

No email / No phone

Status: Recruiting

Research Site

Diyarbakır, 21280, Turkey (Türkiye)

No email / No phone

Status: Recruiting

Research Site

Ankara, 06230, Turkey (Türkiye)

No email / No phone

Status: Recruiting

Research Site

Oxford, OX3 7LE, United Kingdom

No email / No phone

Status: Recruiting

Research Site

London, SW3 6JJ, United Kingdom

No email / No phone

Status: Recruiting

Research Site

London, EC1A 7BE, United Kingdom

No email / No phone

Status: Recruiting

Research Site

Cambridge, CB2 0QQ, United Kingdom

No email / No phone

Status: Recruiting

Research Site

Taunton, TA1 5DA, United Kingdom

No email / No phone

Status: Recruiting

Research Site

Manchester, M20 4BX, United Kingdom

No email / No phone

Status: Recruiting

Research Site

Mobile, Alabama, 36604, United States

No email / No phone

Status: Recruiting

Research Site

Tucson, Arizona, 85719, United States

No email / No phone

Status: Recruiting

Research Site

Newport Beach, California, 92663, United States

No email / No phone

Status: Recruiting

Research Site

Los Angeles, California, 90089, United States

No email / No phone

Status: Recruiting

Research Site

Los Angeles, California, 90048, United States

No email / No phone

Status: Recruiting

Research Site

Irvine, California, 92618, United States

No email / No phone

Status: Recruiting

Research Site

Duarte, California, 91010, United States

No email / No phone

Status: Recruiting

Research Site

Washington D.C., District of Columbia, 20007, United States

No email / No phone

Status: Recruiting

Research Site

Fleming Island, Florida, 32003, United States

No email / No phone

Status: Recruiting

Research Site

Orlando, Florida, 32804, United States

No email / No phone

Status: Recruiting

Research Site

Hollywood, Florida, 33021, United States

No email / No phone

Status: Recruiting

Research Site

Marietta, Georgia, 30060, United States

No email / No phone

Status: Recruiting

Research Site

Honolulu, Hawaii, 96819, United States

No email / No phone

Status: Recruiting

Research Site

Boise, Idaho, 83712, United States

No email / No phone

Status: Recruiting

Research Site

Lexington, Kentucky, 40536, United States

No email / No phone

Status: Recruiting

Research Site

Boston, Massachusetts, 02114, United States

No email / No phone

Status: Recruiting

Research Site

Ann Arbor, Michigan, 48106, United States

No email / No phone

Status: Recruiting

Research Site

Ann Arbor, Michigan, 48109, United States

No email / No phone

Status: Recruiting

Research Site

Kansas City, Missouri, 64111, United States

No email / No phone

Status: Recruiting

Research Site

New York, New York, 10065, United States

No email / No phone

Status: Recruiting

Research Site

Mineola, New York, 11501, United States

No email / No phone

Status: Recruiting

Research Site

New York, New York, 10016, United States

No email / No phone

Status: Recruiting

Research Site

New York, New York, 10032, United States

No email / No phone

Status: Recruiting

Research Site

Philadelphia, Pennsylvania, 19111, United States

No email / No phone

Status: Recruiting

Research Site

York, Pennsylvania, 17403, United States

No email / No phone

Status: Recruiting

Research Site

Fredericksburg, Virginia, 22408, United States

No email / No phone

Status: Recruiting

Research Site

Charlottesville, Virginia, 22908, United States

No email / No phone

Status: Recruiting

Research Site

Olympia, Washington, 98502, United States

No email / No phone

Status: Recruiting

Research Site

Vinh, 460000, Vietnam

No email / No phone

Status: Recruiting

Research Site

Ho Chi Minh City, 700000, Vietnam

No email / No phone

Status: Recruiting

Research Site

Hanoi, 100000, Vietnam

No email / No phone

Status: Recruiting

Research Site

Seoul, 05505, South Korea

No email / No phone

Status: Active, not recruiting

Research Site

Porto Alegre, 91350-200, Brazil

No email / No phone

Status: Not yet recruiting

Research Site

Bengaluru, 560027, India

No email / No phone

Status: Not yet recruiting

Research Site

Modena, 41124, Italy

No email / No phone

Status: Not yet recruiting

Research Site

Calgary, Alberta, T2N 4N2, Canada

No email / No phone

Status: Withdrawn

Research Site

Montreal, Quebec, H3T 1E2, Canada

No email / No phone

Status: Withdrawn

Research Site

Nanjing, 210009, China

No email / No phone

Status: Withdrawn

Research Site

Luoyang, 471003, China

No email / No phone

Status: Withdrawn

Research Site

Changsha, 410013, China

No email / No phone

Status: Withdrawn

Research Site

Dresden, 01067, Germany

No email / No phone

Status: Withdrawn

Research Site

Dresden, 01370, Germany

No email / No phone

Status: Withdrawn

Research Site

Essen, 45136, Germany

No email / No phone

Status: Withdrawn

Research Site

Mainz, 55131, Germany

No email / No phone

Status: Withdrawn

Research Site

Tomaszów Mazowiecki, 97-200, Poland

No email / No phone

Status: Withdrawn

Research Site

Szczecin, 71-730, Poland

No email / No phone

Status: Withdrawn

Research Site

Birmingham, Alabama, 35233, United States

No email / No phone

Status: Withdrawn

Research Site

Fullerton, California, 92835, United States

No email / No phone

Status: Withdrawn

Research Site

Santa Rosa, California, 95403, United States

No email / No phone

Status: Withdrawn

Research Site

Atlanta, Georgia, 30322, United States

No email / No phone

Status: Withdrawn

Research Site

Baltimore, Maryland, 21287, United States

No email / No phone

Status: Withdrawn

Research Site

St Louis, Missouri, 63110, United States

No email / No phone

Status: Withdrawn

Research Site

St Louis, Missouri, 63128, United States

No email / No phone

Status: Withdrawn

Research Site

Cincinnati, Ohio, 45219, United States

No email / No phone

Status: Withdrawn

Research Site

Portland, Oregon, 97239, United States

No email / No phone

Status: Withdrawn

Research Site

Seattle, Washington, 98109, United States

No email / No phone

Status: Withdrawn

Trial Details

Show Summary from Sponsor

More details:

Investigational Drug AI Analysis

Show for: AZD0901 (Sonesitatug vedotin, CMG901)

Overview

Mechanism of action

Efficacy

Safety

Additional notes

Further reading

Show for: Apatinib (Rivoceranib)

Overview

Mechanism of action

Efficacy

Safety

Further reading

HealthScout AI Analysis

Eligibility

Show Criteria

Sites (186)

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site